JP2015227342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015227342A5 JP2015227342A5 JP2015129677A JP2015129677A JP2015227342A5 JP 2015227342 A5 JP2015227342 A5 JP 2015227342A5 JP 2015129677 A JP2015129677 A JP 2015129677A JP 2015129677 A JP2015129677 A JP 2015129677A JP 2015227342 A5 JP2015227342 A5 JP 2015227342A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- disease
- fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013691 Interleukin-17 Human genes 0.000 claims 6
- 108050003558 Interleukin-17 Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 5
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims 5
- 102000053162 human IL17A Human genes 0.000 claims 5
- 102000056946 human IL17F Human genes 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031737 Tissue Adhesions Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000011475 meningoencephalitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0620729.4 | 2006-10-18 | ||
| GBGB0620729.4A GB0620729D0 (en) | 2006-10-18 | 2006-10-18 | Biological products |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013211558A Division JP5856121B2 (ja) | 2006-10-18 | 2013-10-09 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017076759A Division JP2017169569A (ja) | 2006-10-18 | 2017-04-07 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015227342A JP2015227342A (ja) | 2015-12-17 |
| JP2015227342A5 true JP2015227342A5 (enExample) | 2016-06-02 |
| JP6329516B2 JP6329516B2 (ja) | 2018-05-23 |
Family
ID=37507977
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532894A Withdrawn JP2010506580A (ja) | 2006-10-18 | 2007-10-18 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
| JP2013211558A Active JP5856121B2 (ja) | 2006-10-18 | 2013-10-09 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
| JP2015129677A Active JP6329516B2 (ja) | 2006-10-18 | 2015-06-29 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
| JP2017076759A Pending JP2017169569A (ja) | 2006-10-18 | 2017-04-07 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532894A Withdrawn JP2010506580A (ja) | 2006-10-18 | 2007-10-18 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
| JP2013211558A Active JP5856121B2 (ja) | 2006-10-18 | 2013-10-09 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017076759A Pending JP2017169569A (ja) | 2006-10-18 | 2017-04-07 | Ｉｌ−１７ａ及びｉｌ−１７ｆに結合する抗体分子 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US8303953B2 (enExample) |
| EP (3) | EP2076539B1 (enExample) |
| JP (4) | JP2010506580A (enExample) |
| KR (1) | KR20090078355A (enExample) |
| CN (1) | CN101589061B (enExample) |
| AU (1) | AU2007311689B2 (enExample) |
| BR (1) | BRPI0717768B8 (enExample) |
| CA (1) | CA2666458C (enExample) |
| CO (1) | CO6180467A2 (enExample) |
| CY (2) | CY1117963T1 (enExample) |
| DK (2) | DK2514764T3 (enExample) |
| EA (1) | EA029953B1 (enExample) |
| ES (2) | ES2729064T3 (enExample) |
| GB (1) | GB0620729D0 (enExample) |
| HR (2) | HRP20161069T1 (enExample) |
| HU (2) | HUE029448T2 (enExample) |
| IL (1) | IL198061B (enExample) |
| LT (1) | LT2514764T (enExample) |
| MX (1) | MX2009003973A (enExample) |
| PL (2) | PL2514764T3 (enExample) |
| PT (2) | PT2514764T (enExample) |
| RS (1) | RS55031B1 (enExample) |
| SG (1) | SG175652A1 (enExample) |
| SI (2) | SI2076539T1 (enExample) |
| TR (1) | TR201907599T4 (enExample) |
| WO (1) | WO2008047134A2 (enExample) |
| ZA (1) | ZA200902460B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641822B1 (en) | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| EP2377887A1 (en) | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| NO2143225T3 (enExample) | 2007-04-30 | 2018-08-18 | ||
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| KR20170023209A (ko) * | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| JP2012504953A (ja) * | 2008-10-07 | 2012-03-01 | ノビミューン エスアー | Ｉｌ−１７媒介性トランスフェクション法 |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| CN103384682B (zh) | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | 结合il‑17a和il‑17f的抗体分子 |
| CA2826622C (en) | 2011-02-08 | 2021-03-02 | Merck Patent Gmbh | Aminostatin derivatives for the treatment of arthrosis |
| WO2012125680A1 (en) * | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| WO2012138977A1 (en) * | 2011-04-06 | 2012-10-11 | Board Of Trustees Of The Leland Stanford Junior University | Structural based design of il-17 dominant negative mutants |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| DK2858670T3 (en) * | 2012-06-12 | 2018-10-22 | Orega Biotech | Antagonists of IL-17 isoforms and their applications |
| CN104231080B (zh) * | 2013-03-15 | 2019-07-02 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
| GB201310544D0 (en) | 2013-06-13 | 2013-07-31 | Ucb Pharma Sa | Obtaining an improved therapeutic ligand |
| KR102278487B1 (ko) * | 2013-11-18 | 2021-07-19 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Ｉｌ-17ａ 접합체 및 이의 용도 |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| CN107148283A (zh) * | 2014-10-31 | 2017-09-08 | 豪夫迈·罗氏有限公司 | 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN108251431B (zh) | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
| JP6931648B2 (ja) * | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| EA201990673A1 (ru) * | 2016-09-14 | 2019-08-30 | Бэйцзин Ханми Фарм. Ко., Лтд. | Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| GB201919061D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| BR112022026273A2 (pt) | 2020-06-23 | 2023-01-17 | Novartis Ag | Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17) |
| CN112390890B (zh) * | 2020-11-06 | 2022-06-24 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
| IT202200016722A1 (it) * | 2022-08-04 | 2024-02-04 | Paolo Grieco | Nuovo peptide derivato da interleuchina-17A (IL-17A) e anticorpo neutralizzante (Ab17-IPL-1) |
| EP4393948A1 (en) * | 2022-12-28 | 2024-07-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer |
| CN118681005A (zh) * | 2023-03-23 | 2024-09-24 | 上海惠盾因泰生物科技有限公司 | 一种二价il-17治疗性疫苗及其制备方法和应用 |
| TW202515910A (zh) * | 2023-06-22 | 2025-04-16 | 美商派拉岡醫療公司 | Il-17抗體組合物及使用方法 |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GEP19971018B (en) | 1988-06-28 | 1997-04-06 | E I Du Pont De Nemours & Company | Tablet formulations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1053751A1 (en) | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| CA2494383C (en) | 2002-08-16 | 2009-04-07 | Allied Machine & Engineering Corp. | Drilling tool and method for producing port seals |
| EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1641822B1 (en) | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| DK1983000T3 (en) | 2003-11-21 | 2015-12-07 | Ucb Biopharma Sprl | A method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US7910540B2 (en) * | 2004-06-10 | 2011-03-22 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| TW200641353A (en) | 2005-02-14 | 2006-12-01 | Wyeth Corp | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| EP2377887A1 (en) | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7846443B2 (en) | 2006-08-11 | 2010-12-07 | Schering Corporation | Antibodies to IL-17A |
| GB0620729D0 (en) * | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| CN103384682B (zh) * | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | 结合il‑17a和il‑17f的抗体分子 |
-
2006
- 2006-10-18 GB GBGB0620729.4A patent/GB0620729D0/en active Pending
-
2007
- 2007-10-18 MX MX2009003973A patent/MX2009003973A/es active IP Right Grant
- 2007-10-18 ZA ZA200902460A patent/ZA200902460B/xx unknown
- 2007-10-18 RS RS20160641A patent/RS55031B1/sr unknown
- 2007-10-18 EP EP07824232.8A patent/EP2076539B1/en active Active
- 2007-10-18 PT PT12175103T patent/PT2514764T/pt unknown
- 2007-10-18 LT LTEP12175103.6T patent/LT2514764T/lt unknown
- 2007-10-18 EA EA200900492A patent/EA029953B1/ru not_active IP Right Cessation
- 2007-10-18 EP EP12175103.6A patent/EP2514764B1/en active Active
- 2007-10-18 SG SG2011076213A patent/SG175652A1/en unknown
- 2007-10-18 SI SI200731812A patent/SI2076539T1/sl unknown
- 2007-10-18 DK DK12175103.6T patent/DK2514764T3/da active
- 2007-10-18 PL PL12175103T patent/PL2514764T3/pl unknown
- 2007-10-18 EP EP19160793.6A patent/EP3524623A1/en not_active Withdrawn
- 2007-10-18 CN CN200780043116.1A patent/CN101589061B/zh active Active
- 2007-10-18 HR HRP20161069TT patent/HRP20161069T1/hr unknown
- 2007-10-18 HU HUE07824232A patent/HUE029448T2/en unknown
- 2007-10-18 PL PL07824232.8T patent/PL2076539T3/pl unknown
- 2007-10-18 AU AU2007311689A patent/AU2007311689B2/en active Active
- 2007-10-18 US US12/446,143 patent/US8303953B2/en active Active
- 2007-10-18 BR BRPI0717768A patent/BRPI0717768B8/pt active IP Right Grant
- 2007-10-18 PT PT78242328T patent/PT2076539T/pt unknown
- 2007-10-18 KR KR1020097010040A patent/KR20090078355A/ko not_active Withdrawn
- 2007-10-18 TR TR2019/07599T patent/TR201907599T4/tr unknown
- 2007-10-18 DK DK07824232.8T patent/DK2076539T3/da active
- 2007-10-18 CA CA2666458A patent/CA2666458C/en active Active
- 2007-10-18 WO PCT/GB2007/003983 patent/WO2008047134A2/en not_active Ceased
- 2007-10-18 ES ES12175103T patent/ES2729064T3/es active Active
- 2007-10-18 ES ES07824232.8T patent/ES2588596T3/es active Active
- 2007-10-18 SI SI200732113T patent/SI2514764T1/sl unknown
- 2007-10-18 JP JP2009532894A patent/JP2010506580A/ja not_active Withdrawn
- 2007-10-18 HU HUE12175103A patent/HUE043667T2/hu unknown
-
2009
- 2009-04-07 IL IL198061A patent/IL198061B/en active IP Right Grant
- 2009-05-14 CO CO09049372A patent/CO6180467A2/es not_active Application Discontinuation
-
2012
- 2012-10-01 US US13/632,702 patent/US8617847B2/en active Active
-
2013
- 2013-09-24 US US14/035,053 patent/US20140044732A1/en not_active Abandoned
- 2013-10-09 JP JP2013211558A patent/JP5856121B2/ja active Active
- 2013-12-16 US US14/107,314 patent/US20140186355A1/en not_active Abandoned
-
2015
- 2015-05-07 US US14/706,234 patent/US9890219B2/en active Active
- 2015-06-29 JP JP2015129677A patent/JP6329516B2/ja active Active
-
2016
- 2016-09-06 CY CY20161100876T patent/CY1117963T1/el unknown
-
2017
- 2017-04-07 US US15/482,260 patent/US10308723B2/en active Active
- 2017-04-07 JP JP2017076759A patent/JP2017169569A/ja active Pending
-
2019
- 2019-05-21 HR HRP20190932TT patent/HRP20190932T1/hr unknown
- 2019-06-05 CY CY20191100595T patent/CY1121672T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015227342A5 (enExample) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| ME02734B (me) | Antitelo koje vezuje il-17a i il-17f | |
| JP2020513804A5 (enExample) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2019519199A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2010500876A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2012521191A5 (enExample) | ||
| JP2016521688A5 (enExample) | ||
| JP2011527902A5 (enExample) | ||
| FI3283524T3 (fi) | Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle | |
| JP2010534469A5 (enExample) | ||
| CN109311974A (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2018193386A5 (enExample) | ||
| RU2018111508A (ru) | Анти-LAG-3 антитела | |
| JP2017532290A5 (enExample) | ||
| TWI455946B (zh) | 抗磷脂醯肌醇蛋白聚糖３抗體 | |
| RU2018146158A (ru) | Антитела | |
| JP2013539369A5 (enExample) | ||
| JP2016520595A5 (enExample) | ||
| JP2016518333A5 (enExample) | ||
| JP2020511946A5 (enExample) |